Briacell Therapeutics Corp

NASDAQ BCTX

Data sourced from iex and EODHD
Download Data

Briacell Therapeutics Corp Free Cash Flow for the year ending July 31, 2023: USD -23.74 M

Briacell Therapeutics Corp Free Cash Flow is USD -23.74 M for the year ending July 31, 2023, a -90.20% change year over year. Free Cash Flow is the cash flow available to a company after deducting capital expenditures from operating cash flow, indicating its ability to generate cash for expansion, debt repayment, or dividends.
  • Briacell Therapeutics Corp Free Cash Flow for the year ending July 31, 2022 was USD -12.48 M, a -61.14% change year over year.
  • Briacell Therapeutics Corp Free Cash Flow for the year ending July 31, 2021 was USD -7.75 M, a -568.35% change year over year.
  • Briacell Therapeutics Corp Free Cash Flow for the year ending July 31, 2020 was USD -1.16 M, a 70.08% change year over year.
  • Briacell Therapeutics Corp Free Cash Flow for the year ending July 31, 2019 was USD -3.87 M, a -1.81% change year over year.
NASDAQ: BCTX

Briacell Therapeutics Corp

CEO Dr. William V. Williams M.D.
IPO Date Feb. 24, 2021
Location Canada
Headquarters Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1
Employees 16
Sector Healthcare
Industry Biotechnology
Description

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email